32 results about "Synthetase kinase" patented technology

New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

An object of the present invention is to provide a nerve regeneration drug, a neuron regeneration promoter of neural stem cells, a neuron obtained by culturing neural stem cells in the presence of the neuron regeneration promoter, and a method for producing the neuron. In order to achieve this object, the present invention provides a nerve regeneration drug containing a substance that inhibits the activity of glycogen synthase kinase-3 as an active ingredient, a neural stem cell neuron regeneration promoter containing the substance as an active ingredient, and A neuron obtained by culturing neural stem cells in the presence of a neuron regeneration promoting agent and a method for producing the neuron. Medicine of the present invention can be used as Parkinson's disease, Alzheimer's disease, Down's syndrome, cerebrovascular disorder, cerebral apoplexy, spinal cord injury, Huntington's chorea, multiple sclerosis, amyotrophic lateral sclerosis It is used in the treatment of neurological diseases such as neurological disorders, epilepsy, anxiety disorders, complex disorders, depression, and bipolar disorder.

The present invention relates to novel heterocyclic compounds which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

The present invention relates to a new compound of formula (I) wherein R1 is hydrogen or fluoro; R2 and R3 are independently selected from hydrogen or methyl; or a pharmaceutically acceptable salt thereof, pharmaceutical formulations containing said compound, to the use of said active compound in therapy, to the use for the treatment of conditions associated with glycogen synthase kinase-3 related disorders, such as Alzheimer's disease, as well as for the method of treatment of said disorders, comprising administering to a mammal, including human in need of such treatment, a therapeutically effective amount of said compound.

The invention relates to the field of medicine, and discloses a group of biomarkers, kits and applications for predicting the risk of MCI in type 2 diabetes patients. The biomarkers include optic neurin, glycogen synthase kinase-3β, and Ser9-phosphorylated glycogen synthase kinase-3β. The increase of this biomarker can evaluate MCI, which has the characteristics of high accuracy, fast detection speed, low cost, less trauma, and easy acceptance by patients. It provides a scientific and effective early prediction scheme for the occurrence of MCI in patients with type 2 diabetes. The kit can screen for MCI in a wide range of people, and only needs to collect peripheral blood to complete the detection, making it possible to screen for a wide range of elderly population.

The invention discloses a culture method of vascular endothelial progenitor cells, which comprises the following steps: 1) inducing differentiation of multipotent stem cells in a culture medium A to form mesendoderm precursor cells; and 2) inducing differentiation of the mesendoderm precursor cells in a culture medium B to form the vascular endothelial progenitor cells. The culture medium A contains a DMEM (dulbecco's modified eagle medium) culture medium, an F12 culture medium, sodium selenate, sodium bicarbonate, vitamin C, insulin, activin A, a bone formation protein 4 and a glycogen synthetase kinase-3 inhibitor. The culture medium B contains a DMEM culture medium, an F12 culture medium, vitamin C, insulin, a vascular endothelial growth factor and a transforming growth factor beta signal pathway inhibitor. The culture media used in the culture method do not contain any animal-derived component, and can provide sufficient nutrient substances and stable living environments for the cultured cells, thereby efficiently inducing the differentiation of the human multipotent stem cells to form the vascular-grid vascular endothelial progenitor cells which are highly similar to the human cord vessel endothelial cells.

The invention belongs to the field of pharmaceutical chemistry, and discloses 2,3-dihydro[1,5] benzothiazepine compounds of non-adenosine triphosphate (ATP) competitive inhibition glycogen synthase kinase-3beta (GSK-3beta) with a structure shown in formula I. The compounds can inhibit the activity of the GSK-3beta in a non ATP competitive mode, and can be used as micromolecule inhibitors of the GSK-3beta for preparing medicines for preventing or treating GSK-3beta related diseases. The invention further provides applications of the compounds, pharmaceutical acceptable salts thereof, or medicine compositions thereof to preventing or treating the GSK-3beta related diseases. The GSK-3beta related diseases can be diabetes and an Alzheimer's disease.